SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is highly active as bullish investors enthusiastically rally around the CEO's recent comments hinting at "curative outcomes" for its lead AML immunotherapy, GPS, driving significant short squeeze speculation and expectations for imminent positive trial readouts.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is trending with extreme volatility as escalating Middle East tensions and threats to global oil supply from the Strait of Hormuz have driven a sharp price surge. However, community sentiment is now divided between those anticipating sustained higher prices and those expecting a rapid pullback following G7 discussions and actions concerning the release of strategic oil reserves.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing a massive surge after partnering with Novo Nordisk to offer branded GLP-1 weight-loss medications, ending a significant legal dispute and fueling widespread community discussion about a potential short squeeze and a fundamental shift in the company's growth trajectory.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is trending after closing a $40 million private placement, which has ignited a rapid surge in its share price. The community is actively debating the implications of the placement's per-share cost versus current trading levels, with many traders anticipating further momentum and a potential short squeeze.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending as its Cocky Wings LLC real-world asset business actively generates revenue, which the community is celebrating for fueling token buybacks and robust growth within its Cardano-based ecosystem and staking arena.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 interim data for its bladder cancer candidate NDV-01, which showed a durable 76% complete response rate and reinforced plans for Phase 3 trials. This, combined with an oversubscribed $160 million private placement, is driving significant trading volume and community discussion.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending amidst a contentious lawsuit from rival Archer Aviation alleging deceptive ties to Chinese suppliers, even as the company celebrates the official launch of Uber Air in Dubai, signaling a major step towards commercial air taxi service. Community discussion is further fueled by recent earnings highlighting revenue growth and a strong cash runway, with ongoing focus on FAA certification progress and competitive dynamics within the eVTOL sector.

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Calamp Corp.

CAMP4 Therapeutics is capturing significant attention following its oversubscribed $100 million private placement, aimed at advancing its SYNGAP1-related disorder treatment into trials. The community is actively discussing its low float and the potential for a short squeeze, alongside anticipation for upcoming clinical milestones and a recent collaboration with GSK.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

AGH is trending due to its announced merger with drone manufacturer Powerus, a company backed by Eric Trump and Donald Trump Jr., which is transforming it from a golf course operator into a public defense-drone entity. This significant pivot is driving massive community discussion and high volume, fueled by anticipation of government contracts amid increasing demand for U.S.-made drone technology.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is a battleground stock as the community debates whether concerns over rising fuel costs from the Iran war, potentially delaying airline orders, outweigh the impact of a massive rumored aircraft deal from China and anticipated increases in defense spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>uniQure added that the FDA has recommended that the company conduct a prospective, randomized, double-blind, sham-surgery-controlled study.</li><li>The company stated that it intends to continue engaging with the FDA regarding Phase III trial development.</li><li>uniQure added that it plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.</li></ul>uniQure NV (QURE) shares plunged by nearly 45% in Monday’s pre-market trade after the company issued an update about its investigational gene therapy for Huntington’s disease (HD).uniQure said the FDA does not agree that Phase I/II data, compared with an external control, are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/QURE">uniQure</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">FDA Urges Sham-Controlled Trial</h2>uniQure added that the FDA has recommended that the company conduct a prospective, randomized, double-blind, sham-surgery-controlled study.The company stated that it intends to continue engaging with the FDA regarding Phase III trial development. uniQure added that it plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.“We remain committed to engaging with the FDA to determine a clear, scientifically grounded, and efficient path forward for AMT-130,” Kapusta added.<h2 class="st-heading-2">uniQure’s Gene Therapy Pipeline</h2>uniQure currently has six gene therapies in its pipeline, each at different stages of progress and approvals.The company’s Hemophilia B gene therapy, AMT-061, has already been approved, and the AMT-130 therapy for Huntington’s disease is currently at the most advanced stage of trials.uniQure’s other gene therapies include treatments for Fabry disease, Amyotrophic Lateral Sclerosis, and Temporal Lobe Epilepsy, apart from other undisclosed programs.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 35% year-to-date, but up 29% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-aes-stock-falling-today-blackrock-gip-eqt-deal/cZd3EuiRIcw">Why Is AES Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did QURE Stock Almost Halve Pre-Market Today?

uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.

Equity

<ul class="summary-bullets"><li>Analysts said Medicare’s drug-price cuts were smaller or already reflected in forecasts.</li><li>Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.</li><li>Retail traders on Stocktwits turned extremely bullish on LABU as message volume surged.</li></ul>The biotech sector rallied sharply on Wednesday after Wall Street analysts said the latest round of U.S. Medicare drug-price cuts would have a smaller impact on pharmaceutical companies than initially feared, lifting the Direxion Daily S&amp;P Biotech Bull 3X Shares ETF (LABU) to its highest level in nearly 20 months.The&nbsp;<a href="https://stocktwits.com/symbol/LABU">LABU ETF</a> extended its rally on Wednesday, rising 3.7% to close at $165.5 and edging up 0.2% after hours, marking its fourth straight session of gains.<h2 class="st-heading-2">Bernstein Says Semaglutide Pricing Is ‘Final Cloud To Clear’</h2>Shares of major drugmakers jumped after the U.S. government published negotiated Medicare prices for 15 drugs late Tuesday, with cuts of up to 85% scheduled to begin in 2027.Novo Nordisk’s U.S.-listed shares rose&nbsp;nearly 4%, and Teva Pharmaceuticals gained over 5%, after their flagship therapies appeared on the pricing list. Novo’s semaglutide drugs, Ozempic and Wegovy, along with Teva’s Austedo, were included among the treatments subject to reductions.Bernstein analyst Christian Moore said the negotiated price for Novo’s semaglutide was “the final cloud to clear on the drawn-out, but positively resolved GLP-1 pricing debate,” Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-shares-rise-us-medicare-price-cuts-come-largely-expected-2025-11-26/">reported</a>.<h2 class="st-heading-2">Goldman Sachs Says Austedo Cut Milder Than Expected</h2>Goldman Sachs analyst Matt Dellatorre noted that Austedo’s 38% price cut came in lower than the roughly 45% reduction modeled. He said the updated government price, which is a little over $700 lower per monthly supply versus one estimate of its net price, was below expectations and therefore less damaging for Teva.<h2 class="st-heading-2">Guggenheim Flags Deeper Than Expected Cuts For AbbVie</h2>Guggenheim analyst Vamil Divan said AbbVie’s cuts on Linzess and Vraylar, which come up to 75% and 44%, respectively, were deeper than anticipated.Two analysts said they are now watching how Medicare plans will manage access to the first batch of 10 drugs whose new negotiated prices take effect in January 2026, and what the Feb. 1 announcement of the next 15 drugs for 2028 will reveal.<h2 class="st-heading-2">Bernstein, William Blair, And Others Say Impact Already Priced In</h2>Bernstein analysts said five of the 15 targeted medicines will be generic by 2027, limiting exposure to deeper cuts. They added that lower prices could keep patients on branded therapies longer, potentially supporting volumes.William Blair analysts said the $274 monthly Medicare price for Novo’s semaglutide broadly tracks recent government agreements but added that insurance-coverage expansion remains uncertain. Analysts also said reductions had already been reflected in forecasts for Novo Nordisk, AstraZeneca and GSK.&nbsp;Earlier this month, Novo said it expected a low single-digit global sales impact if pricing were implemented this year, which analysts indicated translates to roughly DKK 6 billion.<h2 class="st-heading-2">Liquidity Wave Drives LABU Frenzy On Stocktwits</h2>On Stocktwits, retail sentiment for LABU was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/143;" src="https://news.stocktwits-cdn.com/labu_ss_png_d696fb5c91.webp" alt="labu ss.png" width="970" height="143"><figcaption>LABU sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One user said, “This concentrated burst of purchasing power is pushing up prices.”<stembedurl>https://stocktwits.com/JesusHolbrook/message/637590765</stembedurl>Another user said the move looks close to a blow-off top, possibly around $165–$175, and warned that any pullback could echo the sharp drop seen after the Covid peak.<stembedurl>https://stocktwits.com/bottomfishtrader/message/637525624</stembedurl>The LABU ETF has risen 22% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The LABU ETF has risen 22% so far in 2025. (Photo credit: Getty Images)

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Best-Performing Leveraged ETFs of October 

October's top ETF gainers included the likes of NVTX, AMUU, KORU, LABU and INTW. These ETFs soared as AI, crypto and reform optimism drove markets higher.

<ul class="summary-bullets"><li>The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.</li><li>In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025. &nbsp;</li></ul>The U.S. Food and Drug Administration on Friday said that it has approved Syndax Pharmaceuticals’ (SNDX) Revuforj for some relapsed or refractory acute myeloid leukemia (ACL) patients with particular mutations.The agency <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation">approved</a> the medicine for both adults and pediatric patients one year and older with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. &nbsp;<h2 class="st-heading-2">Implication For Patients, Syndax</h2>According to Syndax, mutations in the NPM1 gene are the most common genetic alteration observed in AML, occurring in approximately 30% of adults with the condition. Patients with the mutation have a poor prognosis, and there are currently no approved therapies that selectively target the underlying disease mechanism driving the cancer, it said.Revuforj was launched in the U.S. in November 2024 for the treatment of a specific type of leukemia called relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. The new FDA approval expands the indication for the drug.In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 4% on Friday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNDX">SNDX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:583/60;" src="data:image/png;base64,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" width="583" height="60" alt="SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the stock is a good buy below $20.<stembedurl>https://stocktwits.com/dcrown/message/633624243</stembedurl>Another raised doubts about the possibility of a major rally.<stembedurl>https://stocktwits.com/Olena/message/633527864</stembedurl>SNDX stock is up by 15% this year but down by about 20% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/teladoc-stock-shoots-up-bofa-views-it-as-differentiated-asset-but-cautious-on-near-term-outlook/cLGJuuUR3ti">Teladoc Stock Shot Up 8% Today: BofA Views It As Differentiated Asset But Remains Cautious On Near-Term Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval 

The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.

Leveraged ETF Areas of Last Week That Are Up At least 15%

Tech rally, weak jobs data and Fed rate cut bets were highlights of last week. Winning leveraged ETFs were GDXU, SOUX, AVGG, GGLL and LABU.

LABU
Direxion Daily S&P Biotech Bull 3X Shares

Feed

News

Sentiment

Fundamentals

Info

Latest LABU News

LABUDirexion Daily S&P Biotech Bull 3X Shares